180TiP - An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer - European Lung Cancer Congress 2019

180TiP - An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer

Advanced NSCLC

180TiP - An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer

Authors

J. Spicer (London, United Kingdom)
M. Provencio (Madrid, Spain)
P. Garrido Lopez (Madrid, Spain)
J. Bosch-Barrera (Girona, Spain)
F. De Castro Carpeño (Madrid, Spain)
E. Felip (Barcelona, Spain)
J. Trigo (Malaga, Spain)
S. Viteri (Barcelona, Spain)
E. Coart (Ottignies, Belgium)
E. Schmidt (Kenilworth, NJ, United States of America)
A. Christiansen (Copenhagen, Denmark)
M. Zocca (Copenhagen, Denmark)
M. Andersen (Copenhagen, Denmark)
E. Ehrnrooth (Copenhagen, Denmark)
L. Paz-Ares (Madrid, Spain)

Speakers

J. Spicer (London, United Kingdom)

Previous ePoster

79P - Tissue microarray analysis on prognostic value of coexpression of RUNX3 and trimethylated histone H3 lysine 27 in surgically resected patients with stage I non-small cell lung cancer

Next ePosters

No ePoster preview available

15P - TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor

No ePoster preview available

80P - High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC)

169P_PR - Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)

73P - Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries

31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer

36P - Can a BALF profile distinguish hot vs cold lung tumors?

8P - Role of chemokines in resectable non-small cell lung cancer (NSCLC)

129P - Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer

22P - Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors

154P - Renal toxicity from platinum/pemetrexed and pembrolizumab in the era of combination therapy